SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kumar R, Haugen JD, Wieben ED, Londowski JM, Cai Q 1995 Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia. Proc Assoc Am Physicians 107: 296305.
  • 2
    Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82: 674681.
  • 3
    Drezner MK 2000 PHEX gene and hypophosphatemia. Kidney Int 57: 918.
  • 4
    ADHR-Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345348.
  • 5
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 49574960.
  • 6
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 16561663.
  • 7
    Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, Tohme JF, Karaplis AC, Clemens TL 1997 Tumor-induced osteomalacia: Clinical and basic studies. J Bone Miner Res 12: 15021511.
  • 8
    Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 12271234.
  • 9
    Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 31793182.
  • 10
    Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N 2003 Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 22062211.
  • 11
    Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421432.
  • 12
    Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561568.
  • 13
    Jan de Beur SM, Finnegan RB, Vassiliadis J 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17: 11021110.
  • 14
    Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL 2000 MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67: 5468.
  • 15
    O'Brien SP, Bowe AE, Byrne A, Weber W, Pragnell M, Kumar R, Schiavi SC 2003 FGF23 and FRP4 internalize sodium-phosphate co-transporter (NaPi2a) in opposum kidney proximal tubule cells. J Bone Miner Res 18: S330.
  • 16
    Berndt T, Craig TA, Bowe AE 2003 Secreted frizzled related protein-4 is a potent tumor derived phosphaturic agent. J Clin Invest 112: 785794.
  • 17
    Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34: 303319.
  • 18
    Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS 2004 Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): Implications for phosphaturia and rickets. J Endocrinol 183: R1R9.
  • 19
    Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS 1998 Hypovitaminosis D in medical inpatients. N Engl J Med 338: 777783.
  • 20
    Bringhurst FR 2001 Regulation of calcium and phosphate homeostasis. DegrootLJ JamesonJL (eds.) Endocrinology. W.B. Saunders, Philadelphia, PA, USA, 10291047.
  • 21
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429435.
  • 22
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 30873094.
  • 23
    Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409414.
  • 24
    Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N 2005 Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 25432549.
  • 25
    Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA 2005 Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 53585364.
  • 26
    Dominguez JH, Gray RW, Lemann J Jr 1976 Dietary phosphate deprivation in women and men: Effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D. J Clin Endocrinol Metab 43: 10561068.
  • 27
    Levi M, Lotscher M, Sorribas V, Custer M, Arar M, Kaissling B, Murer H, Biber J 1994 Cellular mechanisms of acute and chronic adaptation of rat renal P(i) transporter to alterations in dietary P(i). Am J Physiol 267: F900F908.
  • 28
    Kronenberg HM 2002 NPT2a—the key to phosphate homeostasis. N Engl J Med 347: 10221024.
  • 29
    Stamp TC, Stacey TE 1970 Evaluation of theoretical renal phosphorus threshold as an index of renal phosphorus handling. Clin Sci 39: 505516.
  • 30
    Bijvoet OL 1969 Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci 37: 2336.
  • 31
    Pfister MF, Lederer E, Forgo J, Ziegler U, Lotscher M, Quabius ES, Biber J, Murer H 1997 Parathyroid hormone-dependent degradation of type II Na+/Pi cotransporters. J Biol Chem 272: 2012520130.
  • 32
    Miyamoto K, Segawa H, Ito M, Kuwahata M 2004 Physiological regulation of renal sodium-dependent phosphate cotransporters. Jpn J Physiol 54: 93102.
  • 33
    Segawa H, Kawakami E, Kaneko I, Kuwahata M, Ito M, Kusano K, Saito H, Fukushima N, Miyamoto K 2003 Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch 446: 585592.
  • 34
    Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF 1998 Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 95: 13871391.
  • 35
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 65006505.
  • 36
    Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14: 385390.
  • 37
    Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90: 24242427.
  • 38
    Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90: 55235527.
  • 39
    Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M, Koerber F, Topaz O, Bergman R, Sprecher E, Schoenau E 2005 A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 118: 261266.
  • 40
    Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 22722279.
  • 41
    Ferrari SL, Bonjour JP, Rizzoli R 2005 Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 15191524.
  • 42
    Nishida Y, Yamanaka-Okumura H, Taketani Y, Sato T, Nashiki K, Yamamoto T, Takeda E 2005 Postprandial changes of serum fibroblast growth factor 23 levels on high phosphate diet in healthy men. J Bone Miner Res 20: S344.
  • 43
    Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H, Goto H, Miki T, Ishimura E, Sugimoto T, Ishikawa T, Inaba M, Nishizawa Y 2006 Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154: 9399.
  • 44
    Tebben PJ, Singh RJ, Clarke BL, Kumar R 2004 Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79: 15081513.
  • 45
    Singh RJ, Kumar R 2003 Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78: 826829.
  • 46
    Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M, Noguchi S 2004 Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151: 5560.
  • 47
    Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89: 44894492.
  • 48
    Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ 1996 Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 25342540.
  • 49
    Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T 2005 Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23: 435440.
  • 50
    Sommer S, Berndt T, Singh R, Kumar R 2005 Rapid in vivo integrated hormonal responses to alterations in dietary phosphate intake. J Bone Miner Res 20: S306.
  • 51
    Antoniucci D, Sellmeyer D, Yamashita T, Portale A 2005 Dietary phosphate regulates serum FGF-23 concentrations in healthy men. J Bone Miner Res 20: S345.
  • 52
    Geller J, Cutler C, Kelly M, Adams J, Collins M 2005 Cinacalcet is associated with decreased serum FGF-23 and improved phosphorus homeostasis in patients with tumor-induced osteomalacia. J Bone Miner Res 20: S177.